EXECUTIVE INTERVIEWS

  • Balancing Biopharma’s Bright Future Against Its Tarnished Image —  Insights From 6 Retired CEOs
    Balancing Biopharma’s Bright Future Against Its Tarnished Image — Insights From 6 Retired CEOs

    Find out what life is like after retiring from a pharma CEO role. These 6 leaders  speak — unrestrained by corporate lawyers and PR teams — about the current state of the industry.

  • CEOs 40 & Under: The Future of Pharma Innovation
    CEOs 40 & Under: The Future of Pharma Innovation

    To take the pulse of the biopharma industry, Life Science Leader tracked down four CEOs age 40 and under. These are the people at the forefront of innovation — something that is no easy task in a heavily regulated, patient-centered industry. Biotech is not tech. Heading up a company that is developing a pharmaceutical is a lot more challenging and riskier than starting one in your garage that is developing the next mobile phone app.

  • Astellas Puts Oncology Front & Center
    Astellas Puts Oncology Front & Center

    Astellas has placed a big emphasis on oncology this year, pointing to its many assets, particularly in targeted therapies that are later stage, but also focusing through partnerships on immuno-oncology (IO). A conversation with Drs. Steven Benner, head of oncology, and Peter Sandor, head of oncology marketing strategy, follows.

  • IO KOLs Speak On
    IO KOLs Speak On

    More thoughts and comments from cancer immunotherapy experts augment our 2017 immuno-oncology update.

  • How Pfizer And Zoetis Launched One Of The Most Successful Spinoffs — Ever
    How Pfizer And Zoetis Launched One Of The Most Successful Spinoffs — Ever

    The story of how Juan Ramón Alaix was groomed for his CEO role and how Zoetis turned into the world’s largest publicly traded animal health company.

  • Can DalCor Pharma Succeed Where Others Have Failed?
    Can DalCor Pharma Succeed Where Others Have Failed?

    After the worldwide success of statins, no one expected the epic failure of a class of drugs designed by the biggest names in Big Pharma to double the reduction in cardiac risk seen with statins alone. Statins lowered LDL, the bad cholesterol. The new drugs, called cholesteryl ester transfer protein (CETP) inhibitors, would raise HDL, the good cholesterol. Taken together, the drugs would reduce risk of cardiovascular events by up to 80 percent — or at least that was the idea.

  • Amorsa’s Self-Funded Path To Big Pharma Partnerships
    Amorsa’s Self-Funded Path To Big Pharma Partnerships

    By some estimates, it costs about $10 million per year to operate a startup pharmaceutical company. Funding that traditional path usually involves obtaining nondilutive grant funding, then angel investment, followed by a Series A round, and, if all goes well with the science, a strategic partnership with a large pharmaceutical firm to develop the company’s lead compound. Increasingly, however, pharmaceutical entrepreneurs are creating new ways of skipping some of these steps — ones that cost time, money, and ownership stakes in their own companies.

  • Our Annual Cancer Immunotherapy Update
    Our Annual Cancer Immunotherapy Update

    When we started our series, “Combination Cancer Immunotherapy — A Virtual Roundtable,” in 2014, our basic assumptions were not the consensus view. We assumed immunotherapy, now more commonly called immuno-oncology (IO), would become the dominant form of cancer treatment and central target of academic and industry research in oncology. We assumed a single, backbone therapy would become the pillar around which combinations of therapeutics with complementary targets would form. And we assumed the IO field, especially in its combination approaches, would pose profound scientific and business challenges as it took over as the central focus of oncology in general. Our assumptions turned out to be correct. Now, all IO has to do is catch up with itself.

  • Purdue’s SVP Of R&D Talks Opioid Abuse, New Pain Treatments
    Purdue’s SVP Of R&D Talks Opioid Abuse, New Pain Treatments

    Alan Dunton, M.D., joined Purdue Pharma as the SVP of R&D back in November 2015. An executive with over 33 years of discovery and development experience, he has been responsible for the approval of more than 20 prescription and OTC products. But now he faces a new challenge. Purdue Pharma is a company whose name has become synonymous with pain management.

  • How Zoetis Built Its Own Corporate Culture
    How Zoetis Built Its Own Corporate Culture

    In 2012, Pfizer announced a big decision — It was spinning off its $4 billion animal health business. Life Science Leader will explore the difficult task of such an undertaking in our June 2017 issue. And while the article, How Pfizer And Zoetis Launched One Of The Most Successful Spinoffs — Ever, discusses a lot of the important business decisions that were made, one thing not covered in great detail was the opportunity for Zoetis to build a corporate culture of its own.

More Executive Interviews

LIFE SCIENCE EVENTS

Clinical Study Requirements – Understanding Differences Between the US and EU July 25, 2017
1pm-2:30pm EST, Online Training
Price:  $299 - Includes Bonus Handouts!
NGS and Clinical Applications Congress: USA July 25 - 26, 2017
Philadelphia, PA
Medical Affairs Leaders Forum USA July 25 - 27, 2017
Princeton, NJ
Simplifying Your Quality System While Implementing ISO 13485:2016 Requirements – Strategies for Success July 27, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Drug Development 101 – How A Drug Is Made August 3, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Aquaculture Conference August 7 - 9, 2017
Rome, NV
ICH E6 Addendum R2 Team Training and Action Planning August 7, 2017
11:00am- 12:00pm EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
Cell Therapy: Process Design Considerations To Support Commercialization August 9, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Effective Batch Record Review - Getting It Right The First Time August 14, 2017
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Using Social Media for Patient Recruitment in Clinical Trials August 15, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
CAPA and Root Cause Analysis Essentials Post ICH GCP E6 (R2) Addendum August 21, 2017
11:00am- 12:00pm EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
Outsourced Pharma August 22 - 23, 2017
San Diego, CA
How To Establish The Number of Runs Required For Process Validation August 23, 2017
1:00 - 2:00 PM EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
Monitoring Plan Development: Post ICH GCP E6 (R2) Addendum August 25, 2017
11:00am- 12:00pm EDT, Online Training
Duration:  60 Minutes
Price:  $299 - Includes Bonus Handouts!
FDA GMP Inspections – Proven Preparation & Survival Techniques August 29, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Natalie James September 4, 2017
Paris
Mobile In Clinical Trials September 6, 2017
Boston, MA